drugset / Trial / NCT00413153

Metabolic Effects of Switching Kaletra to Boosted Reyataz

NCT00413153 ↗

RandomizedParallel-groupOpen-labelTreatment

Summary

To study the effects of switching from Kaletra to Boosted Reyataz on glucose, lipids and fat in HIV-infected patients.

Timeline

Start
2006-05
Primary completion
2008-12
Completion
2008-12

Drugs

EvaluationDrugModalityDoseRoute
Comparator Atazanavir Other / unclassified 300 mg —
Comparator Lopinavir Other / unclassified — —
Comparator Ritonavir Other / unclassified 100 mg —
Comparator Ritonavir Other / unclassified — —